{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T06:23:51Z","timestamp":1787379831147,"version":"build-2736575974"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,21]]},"DOI":"10.7759\/cureus.114959","type":"journal-article","created":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T05:40:36Z","timestamp":1787377236000},"source":"Crossref","is-referenced-by-count":0,"title":["Original rDNA Semaglutide Versus Synthetic Copies: Differences and Clinical Implications"],"prefix":"10.7759","author":[{"given":"Viswanathan","family":"Mohan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay","family":"Ahluwalia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyan  K","family":"Gangopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpandev","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Banshi","family":"Saboo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jothydev","family":"Kesavadev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santosh","family":"Ramakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Om J","family":"Lakhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Nagendra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhay Kumar","family":"Sahoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameya","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagesh","family":"V. Sri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shashank R","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Development and Manufacture of Synthetic Peptides: Scientific Guideline","author":"European Medicines Agency","year":"2025","unstructured":"European Medicines Agency. Development and Manufacture of Synthetic Peptides: Scientific Guideline. European Medicines Agency, Amsterdam; 2025."},{"key":"ref2","article-title":"Annual Report","author":"Novo Nordisk A\/S","year":"2023","unstructured":"Novo Nordisk A\/S. Annual Report. Novo Nordisk A\/S, Bagsv\u00e6rd; 2023."},{"key":"ref3","article-title":"Abbott Partners With Novo Nordisk India to Launch Extensior\u00ae, Broadening Access to Semaglutide (Ozempic\u00ae) for Advanced Diabetes Management","author":"Abbott India Ltd.","year":"2026","unstructured":"Abbott India Ltd.. Abbott Partners With Novo Nordisk India to Launch Extensior\u00ae, Broadening Access to Semaglutide (Ozempic\u00ae) for Advanced Diabetes Management. Abbott India, 2026."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.47391\/JPMA.25-61","article-title":"Pharmacosimilars in obesity medicine: informed choice, appropriate choice","volume":"75","author":"Kalra S","year":"2025","unstructured":"Kalra S, Singh A, Kapoor N. Pharmacosimilars in obesity medicine: informed choice, appropriate choice. J Pak Med Assoc. 2025, 75:1293-5. 10.47391\/JPMA.25-61","journal-title":"J Pak Med Assoc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.164033","article-title":"Biosimilar insulins: Informed choice for South Asia","volume":"20","author":"Kalra S","year":"2016","unstructured":"Kalra S, Azad Khan AK, Raza SA, et al.. Biosimilar insulins: Informed choice for South Asia. Indian J Endocrinol Metab. 2016, 20:5-8. 10.4103\/2230-8210.164033","journal-title":"Indian J Endocrinol Metab"},{"key":"ref6","article-title":"FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated With Compounded Injectable Semaglutide Products","author":"U.S. Food and Drug Administration","year":"2024","unstructured":"U.S. Food and Drug Administration. FDA Alerts Health Care Providers, Compounders and Patients of Dosing Errors Associated With Compounded Injectable Semaglutide Products. U.S. Food and Drug Administration, Silver Spring, MD; 2024."},{"key":"ref7","article-title":"FDA\u2019s Concerns With Unapproved Glp-1 Drugs Used for Weight Loss: U.S","author":"U.S. Food and Drug Administration","year":"2025","unstructured":"U.S. Food and Drug Administration. FDA\u2019s Concerns With Unapproved Glp-1 Drugs Used for Weight Loss: U.S. U.S. Food and Drug Administration, Silver Spring, MD; 2025."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex278","article-title":"The process defines the product: what really matters in biosimilar design and production?","volume":"56","author":"Vulto AG","year":"2017","unstructured":"Vulto AG, Jaquez OA. The process defines the product: what really matters in biosimilar design and production?. Rheumatology (Oxford). 2017, 56:iv14-29. 10.1093\/rheumatology\/kex278","journal-title":"Rheumatology (Oxford)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.12.051","article-title":"Building parity between brand and generic peptide products: Regulatory and scientific considerations for quality of synthetic peptides","volume":"518","author":"Wu LC","year":"2017","unstructured":"Wu LC, Chen F, Lee SL, Raw A, Yu LX. Building parity between brand and generic peptide products: Regulatory and scientific considerations for quality of synthetic peptides. Int J Pharm. 2017, 518:320-34. 10.1016\/j.ijpharm.2016.12.051","journal-title":"Int J Pharm"},{"key":"ref10","article-title":"Guideline for Approval of Synthetically Manufactured Drug Which Has Been Previously Approved as r-DNA Derived Drug","author":"Central Drugs Standard Control Organization","year":"2019","unstructured":"Central Drugs Standard Control Organization. Guideline for Approval of Synthetically Manufactured Drug Which Has Been Previously Approved as r-DNA Derived Drug. Central Drugs Standard Control Organization, New Delhi; 2019."},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/30502071261447663","article-title":"Editorial: Sema-glu(t)-tide in India","author":"Seshadri KG","year":"2026","unstructured":"Seshadri KG, Joshi SR, Sosale AR. Editorial: Sema-glu(t)-tide in India. Int J Clin Metab Diabetes. 2026, 10.1177\/30502071261447663","journal-title":"Int J Clin Metab Diabetes"},{"key":"ref12","unstructured":"U.S. Food and Drug Administration. Sameness evaluations in an ANDA\u2014active ingredients. draft guidance for industry. (2022). https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/sameness-evaluations-anda-active-ingredients."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-020-02817-9","article-title":"Influence of production process and scale on quality of polypeptide drugs: a case study on GLP-1 analogs","volume":"37","author":"Staby A","year":"2020","unstructured":"Staby A, Steensgaard DB, Haselmann KF, et al.. Influence of production process and scale on quality of polypeptide drugs: a case study on GLP-1 analogs. Pharm Res. 2020, 37:120. 10.1007\/s11095-020-02817-9","journal-title":"Pharm Res"},{"key":"ref14","article-title":"Ozempic 0.5 mg Solution for Injection in Pre-Filled Pen: Summary of Product Characteristics","author":"Electronic Medicines Compendium","year":"2025","unstructured":"Electronic Medicines Compendium. Ozempic 0.5 mg Solution for Injection in Pre-Filled Pen: Summary of Product Characteristics. Electronic Medicines Compendium, 2025."},{"key":"ref15","article-title":"Rybelsus 3 mg: Summary of Product Characteristics","author":"Electronic Medicines Compendium","year":"2025","unstructured":"Electronic Medicines Compendium. Rybelsus 3 mg: Summary of Product Characteristics. Electronic Medicines Compendium, 2025."},{"key":"ref16","article-title":"Wegovy Solution for Injection in Pre-Filled Pen: Summary of Product Characteristics","author":"Electronic Medicines Compendium","year":"2025","unstructured":"Electronic Medicines Compendium. Wegovy Solution for Injection in Pre-Filled Pen: Summary of Product Characteristics. Electronic Medicines Compendium, 2025."},{"key":"ref17","article-title":"Biologics and Biosimilars: An Overview","author":"Amgen Inc.","year":"2017","unstructured":"Amgen Inc.. Biologics and Biosimilars: An Overview. Amgen Inc., Thousand Oaks, CA; 2017."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.5639\/gabij.2012.0101.005","article-title":"Biologicals and biosimilars: a review of the science and its implications","volume":"1","author":"Declerck PJ","year":"2012","unstructured":"Declerck PJ. Biologicals and biosimilars: a review of the science and its implications. Generics Biosimilars Initiat J. 2012, 1:13-6. 10.5639\/gabij.2012.0101.005","journal-title":"Generics Biosimilars Initiat J"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1797.2006.00594.x","article-title":"Biosimilars: how similar or dissimilar are they?","volume":"11","author":"Roger SD","year":"2006","unstructured":"Roger SD. Biosimilars: how similar or dissimilar are they?. Nephrology (Carlton). 2006, 11:341-6. 10.1111\/j.1440-1797.2006.00594.x","journal-title":"Nephrology (Carlton)"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14718","article-title":"Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector","volume":"24","author":"Snitker S","year":"2022","unstructured":"Snitker S, Andersen A, Lindskov PS, van Marle S, Sode BF, Sparre T. Comparison of the injection-site experience of semaglutide in a single-dose and a multidose pen-injector. Diabetes Obes Metab. 2022, 24:1643-6. 10.1111\/dom.14718","journal-title":"Diabetes Obes Metab"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2011.0110","article-title":"A prefilled insulin pen with a novel injection mechanism and a lower injection force than other prefilled insulin pens","volume":"13","author":"Hemmingsen H","year":"2011","unstructured":"Hemmingsen H, Niemeyer M, Hansen MR, Bucher D, Thomsen NB. A prefilled insulin pen with a novel injection mechanism and a lower injection force than other prefilled insulin pens. Diabetes Technol Ther. 2011, 13:1207-11. 10.1089\/dia.2011.0110","journal-title":"Diabetes Technol Ther"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding JP","year":"2021","unstructured":"Wilding JP, Batterham RL, Calanna S, et al.. Once-weekly semaglutide in adults with overweight or obesity\r\n. N Engl J Med. 2021, 384:989-1002. 10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1586\/erd.12.13","article-title":"FlexTouch\u00ae for the delivery of insulin: technical attributes and perception among patients and healthcare professionals","volume":"9","author":"Bailey T","year":"2012","unstructured":"Bailey T, Campos C. FlexTouch\u00ae for the delivery of insulin: technical attributes and perception among patients and healthcare professionals. Expert Rev Med Devices. 2012, 9:209-17. 10.1586\/erd.12.13","journal-title":"Expert Rev Med Devices"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1089\/dia.2017.0121","article-title":"FlexTouch: an insulin pen-injector with a low activation force across different insulin formulations, needle technologies, and temperature conditions","volume":"19","author":"Gudiksen N","year":"2017","unstructured":"Gudiksen N, Hofst\u00e4tter T, R\u00f8nn BB, Sparre T. FlexTouch: an insulin pen-injector with a low activation force across different insulin formulations, needle technologies, and temperature conditions. Diabetes Technol Ther. 2017, 19:603-7. 10.1089\/dia.2017.0121","journal-title":"Diabetes Technol Ther"},{"key":"ref25","article-title":"Generic Drugs: Questions & Answers","author":"U.S. Food and Drug Administration","year":"2025","unstructured":"U.S. Food and Drug Administration. Generic Drugs: Questions & Answers. U.S. Food and Drug Administration, Silver Spring, MD; 2025."},{"key":"ref26","article-title":"WHO Model Guidance for the Storage and Transport of Time- And Temperature-Sensitive Pharmaceutical Products","author":"World Health Organization","year":"2014","unstructured":"World Health Organization. WHO Model Guidance for the Storage and Transport of Time- And Temperature-Sensitive Pharmaceutical Products. World Health Organization, Geneva; 2014."},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2020.88554","article-title":"Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care","volume":"26","author":"Rodbard HW","year":"2020","unstructured":"Rodbard HW, Dougherty T, Taddei-Allen P. Efficacy of oral semaglutide: overview of the PIONEER clinical trial program and implications for managed care. Am J Manag Care. 2020, 26:S335-43. 10.37765\/ajmc.2020.88554","journal-title":"Am J Manag Care"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901118","article-title":"Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain M","year":"2019","unstructured":"Husain M, Birkenfeld AL, Donsmark M, et al.. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019, 381:841-51. 10.1056\/NEJMoa1901118","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso SP","year":"2016","unstructured":"Marso SP, Bain SC, Consoli A, et al.. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016, 375:1834-44. 10.1056\/NEJMoa1607141","journal-title":"N Engl J Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino D","year":"2021","unstructured":"Rubino D, Abrahamsson N, Davies M, et al.. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021, 325:1414-25. 10.1001\/jama.2021.3224","journal-title":"JAMA"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff AM","year":"2023","unstructured":"Lincoff AM, Brown-Frandsen K, Colhoun HM, et al.. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023, 389:2221-32. 10.1056\/NEJMoa2307563","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic V","year":"2024","unstructured":"Perkovic V, Tuttle KR, Rossing P, et al.. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med. 2024, 391:109-21. 10.1056\/NEJMoa2403347","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2501006","article-title":"Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes","volume":"392","author":"McGuire DK","year":"2025","unstructured":"McGuire DK, Marx N, Mulvagh SL, et al.. Oral semaglutide and cardiovascular outcomes in high-risk type 2 diabetes. N Engl J Med. 2025, 392:2001-12. 10.1056\/NEJMoa2501006","journal-title":"N Engl J Med"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00509-4","article-title":"Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial","volume":"405","author":"Bonaca MP","year":"2025","unstructured":"Bonaca MP, Catarig AM, Houlind K, et al.. Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial. Lancet. 2025, 405:1580-93. 10.1016\/S0140-6736(25)00509-4","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258","article-title":"Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis","volume":"392","author":"Sanyal AJ","year":"2025","unstructured":"Sanyal AJ, Newsome PN, Kliers I, et al.. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis. N Engl J Med. 2025, 392:2089-99. 10.1056\/NEJMoa2413258","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf114","article-title":"Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease","volume":"40","author":"Cherney DZ","year":"2025","unstructured":"Cherney DZ, Belmar N, Bjornstad P, et al.. Rationale, design and baseline characteristics of REMODEL, a mechanism-of-action trial with semaglutide in people with type 2 diabetes and chronic kidney disease. Nephrol Dial Transplant. 2025, 40:2182-92. 10.1093\/ndt\/gfaf114","journal-title":"Nephrol Dial Transplant"},{"key":"ref37","unstructured":"Renal & Urology News. How GLP-1 RAs protect kidney function in CKD with T2DM revealed in REMODEL trial. (2025). https.\/\/www.renalandurologynews.com\/reports\/chronic-kidney-disease-ckd-diabetes-glp1-ra-protect-kidney-function\/."}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/506539-original-rdna-semaglutide-versus-synthetic-copies-differences-and-clinical-implications","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T05:40:37Z","timestamp":1787377237000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/506539-original-rdna-semaglutide-versus-synthetic-copies-differences-and-clinical-implications"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":37,"URL":"https:\/\/doi.org\/10.7759\/cureus.114959","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,21]]}}}